You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for HMS5552

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for HMS5552?

HMS5552 is an investigational drug.

There have been 11 clinical trials for HMS5552. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2017.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Hua Medicine Limited, Tigermed Consulting Co., Ltd, and Covance.

There are two US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for HMS5552
Drug Interaction Study Between Dorzagliatin and EmpagliflozinHua Medicine LimitedPhase 1
Drug Interaction Study Between Dorzagliatin and SitagliptinHua Medicine LimitedPhase 1
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of DorzagliatinHua Medicine LimitedPhase 1

See all HMS5552 clinical trials

Clinical Trial Summary for HMS5552

Top disease conditions for HMS5552
Top clinical trial sponsors for HMS5552

See all HMS5552 clinical trials

US Patents for HMS5552

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HMS5552   Start Trial Pyrrolidinone glucokinase activators Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
HMS5552   Start Trial Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine HUA MEDICINE (Grand Gayman, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HMS5552

Drugname Country Document Number Estimated Expiration Related US Patent
HMS5552 Argentina 071474 2028-04-16   Start Trial
HMS5552 Austria 557017 2028-04-16   Start Trial
HMS5552 Australia 2009237794 2028-04-16   Start Trial
HMS5552 Brazil PI0911035 2028-04-16   Start Trial
HMS5552 Canada 2720524 2028-04-16   Start Trial
HMS5552 Chile 2009000889 2028-04-16   Start Trial
HMS5552 China 102007118 2028-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.